Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Statera Biopharma, Inc. (CBLI)
|
Add to portfolio |
|
|
|
| Price: |
$2.14
| | Metrics |
| OS: |
54.7
|
M
| |
|
|
| Market cap: |
$117
|
M
| |
|
|
|
Net debt:
|
$5.89
|
M
| |
|
|
|
EV:
|
$123
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 1.5 | 0.0 | 1.1 | 1.1 | 1.9 | 3.5 | 2.7 | 3.7 |
| Revenue growth | | -100.0% | -2.2% | -41.6% | -44.6% | 29.9% | -26.8% | -56.4% |
| Cost of goods sold | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | -9.9 | 0.0 | 0.0 |
| Gross profit | 1.0 | 0.0 | 1.1 | 1.1 | 1.9 | 13.4 | 2.7 | 3.7 |
| Gross margin | 67.2% | | 100.0% | 100.0% | 100.0% | 381.8% | 100.0% | 100.0% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 0.1 | 0.0 | | | | | | |
| Research and development | 11.8 | 5.3 | 1.7 | 3.6 | 5.0 | 6.5 | 7.1 | 9.7 |
| General and administrative | 19.8 | 5.2 | 1.8 | 2.3 | 2.5 | 3.4 | 6.4 | 8.5 |
| EBITA | -30.5 | -10.5 | -2.4 | -4.8 | -5.6 | -6.3 | -11.0 | 0.1 |
| EBITA margin | -2051.7% | | -212.0% | -421.7% | -287.5% | -179.5% | -406.8% | 3.8% |
| Amortization of intangibles | 0.2 | | | | | | 0.1 | 0.6 |
| EBIT | -30.7 | -10.5 | -2.4 | -4.8 | -5.6 | -6.3 | -11.2 | -0.5 |
| EBIT margin | -2067.4% | | -212.0% | -421.7% | -287.5% | -179.5% | -411.8% | -13.5% |
| Pre-tax income | -101.9 | -12.1 | -2.7 | -3.7 | -9.8 | -2.6 | -13.0 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Earnings from continuing ops | -101.9 | -12.1 | -2.6 | -3.6 | -9.7 | -2.7 | -12.6 | 1.6 |
| Earnings from discontinued ops | 0.0 | | | | | | | |
| Net income | -101.9 | -12.1 | -2.6 | -3.6 | -9.7 | -2.7 | -12.6 | 1.6 |
| Net margin | -6849.3% | | -237.7% | -317.3% | -498.2% | -75.6% | -466.6% | 44.0% |
| |
| Diluted EPS | ($2.90) | ($1.66) | ($0.23) | ($0.32) | ($0.87) | ($0.24) | ($1.79) | $0.60 |
| Shares outstanding (diluted) | 35.1 | 7.3 | 11.3 | 11.3 | 11.2 | 11.0 | 7.1 | 2.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|